BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1108 related articles for article (PubMed ID: 12724482)

  • 21. ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
    Trojani A; Montillo M; Nichelatti M; Tedeschi A; Colombo C; Veronese S; Mura MA; Ricci F; Scarpati B; Colosimo A; Lodola M; Morra E
    Cancer Biomark; 2010; 6(1):1-9. PubMed ID: 20164537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
    Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
    Carreras J; Villamor N; Colomo L; Moreno C; Ramón y Cajal S; Crespo M; Tort F; Bosch F; López-Guillermo A; Colomer D; Montserrat E; Campo E
    J Pathol; 2005 Mar; 205(4):507-13. PubMed ID: 15685592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia.
    Francis S; Karanth M; Pratt G; Starczynski J; Hooper L; Fegan C; Pepper C; Valcarcel D; Milligan DW; Delgado J
    Cancer; 2006 Sep; 107(5):1023-33. PubMed ID: 16862572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis.
    Best OG; Ibbotson RE; Parker AE; Davis ZA; Orchard JA; Oscier DG
    Cytometry B Clin Cytom; 2006 Jul; 70(4):235-41. PubMed ID: 16906573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory.
    Gibbs G; Bromidge T; Howe D; Hopkins J; Johnson S
    Clin Lab Haematol; 2005 Aug; 27(4):258-66. PubMed ID: 16048494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
    J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia.
    Ferrer A; Ollila J; Tobin G; Nagy B; Thunberg U; Aalto Y; Vihinen M; Vilpo J; Rosenquist R; Knuutila S
    Cancer Genet Cytogenet; 2004 Aug; 153(1):69-72. PubMed ID: 15325098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia.
    Friedrichs B; Siegel S; Reimer R; Barsoum A; Coggin J; Kabelitz D; Heidorn K; Schulte C; Schmitz N; Zeis M
    Leuk Res; 2011 Jun; 35(6):721-9. PubMed ID: 21055809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
    Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
    Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
    Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
    Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status.
    Van Bockstaele F; Janssens A; Piette A; Callewaert F; Pede V; Offner F; Verhasselt B; Philippé J
    Cytometry B Clin Cytom; 2006 Jul; 70(4):302-8. PubMed ID: 16906582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia.
    Sulda ML; Kuss BJ; Hall RK; Bailey S; Macardle PJ
    Intern Med J; 2012 Feb; 42(2):137-46. PubMed ID: 20561095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.
    Terrin L; Trentin L; Degan M; Corradini I; Bertorelle R; Carli P; Maschio N; Bo MD; Noventa F; Gattei V; Semenzato G; De Rossi A
    Leukemia; 2007 May; 21(5):965-72. PubMed ID: 17344921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia.
    Del Giudice I; Morilla A; Osuji N; Matutes E; Morilla R; Burford A; Maravelaki S; Owusu-Ankomah K; Swansbury J; A'Hern R; Brito-Babapulle V; Catovsky D
    Cancer; 2005 Nov; 104(10):2124-32. PubMed ID: 16211545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining the clinical course and outcome in chronic lymphocytic leukemia.
    Rai KR; Chiorazzi N
    N Engl J Med; 2003 May; 348(18):1797-9. PubMed ID: 12724486
    [No Abstract]   [Full Text] [Related]  

  • 39. MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal.
    Marquez ME; Deglesne PA; Suarez G; Romano E
    Int J Lab Hematol; 2011 Apr; 33(2):194-200. PubMed ID: 20942870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
    Kim SZ; Chow KU; Kukoc-Zivojnov N; Boehrer S; Brieger A; Steimle-Grauer SA; Harder L; Hoelzer D; Mitrou PS; Weidmann E
    Leuk Lymphoma; 2004 Oct; 45(10):2037-45. PubMed ID: 15370248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.